Assessment of JC virus DNA in blood and urine from natalizumab-treated patients

Annals of Neurology

Volumn 69, Issue 1, 2011, Pages 215-216

  Warnke, Clemens ^a   Adams, Ortwin ^a   Hartung, Hans Peter ^a   Kieseier, Bernd C ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

NATALIZUMAB; VIRUS DNA;

BLOOD SAMPLING; CEREBROSPINAL FLUID; DNA DETERMINATION; HIGH RISK PATIENT; HUMAN; JC VIRUS; LETTER; MULTIPLE SCLEROSIS; NONHUMAN; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RISK ASSESSMENT; URINALYSIS; VIREMIA; VIRUS DETECTION;

ANTIBODIES, MONOCLONAL; DNA, VIRAL; FOLLOW-UP STUDIES; HUMANS; INTEGRIN ALPHA4; JC VIRUS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MULTIPLE SCLEROSIS; POLYMERASE CHAIN REACTION; RISK FACTORS;

EID: 79551483845     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.22305     Document Type: Letter

References (3)

1. Rudick RA, O'Connor PW, Polman CH, etal. Assessment of JC virus DNA in blood and urine from natalizumab-treated patients. Ann Neurol 2010; 68: 304-310.
2. Ryschkewitsch C, Jensen P, Hou J, etal. Comparison of PCR-Southern hybridization and quantitative real-time PCR for the detection of JC and BK viral nucleotide sequences in urine and cerebrospinal fluid. J Virol Methods 2004; 121: 217-221.
3. Warnke C, Smolianov V, Dehmel T, etal. CD34+ progenitor cells mobilized by natalizumab are not a relevant reservoir for JC virus. Mult Scler (in press).